Trial Adds Gemcitabine to Pleural Mesothelioma HIOC Therapy
Results of a phase I clinical trial highlight how the addition of a drug to an existing treatment option appears safe and may improve outcomes in certain patients with malignant pleural mesothelioma (MPM). The primary goal of the trial was to determine the maximum tolerated dose of gemcitabine added to cisplatin when these drugs are delivered together as heated intraoperative chemotherapy (HIOC) during surgery. Researchers have studied cisplatin alone for HIOC. The addition of gemcitabine — a chemotherapy drug often used to treat pancreatic, ovarian and breast cancers — is new. The Journal of Thoracic Oncology...
Source: Asbestos and Mesothelioma News - July 18, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Researchers Find Link Between Vitamin D and Asbestosis
This study was not designed to explain whether supplementing with vitamin D will protect against asbestosis. This new research also does not examine if taking vitamin D will slow down the progression of existing ILD. Still, there are a lot of good reasons to pay attention to the sunshine vitamin. Regardless of whether a person has been exposed to asbestos, no one should ignore very low vitamin D levels. People already diagnosed with an asbestos-related cancer, may benefit from a quick check of vitamin D levels. According to the medical literature, up to 80 percent of people with cancer may be vitamin D deficient. People ca...
Source: Asbestos and Mesothelioma News - July 16, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

J & J Hit with $4.7B Verdict in Talc Asbestos Cancer Case
A Missouri jury Thursday ordered Johnson & Johnson to pay $4.69 billion to 22 women who claim asbestos in the company’s talc products caused them to develop ovarian cancer. It is the largest verdict to date the consumer goods giant has faced in an asbestos-talc case. The Circuit Court of the City of St. Louis handed down $550 million in compensatory damages and $4.14 billion in punitive damages in the verdict, averaging about $25 million apiece for the 22 plaintiffs. J&J currently faces roughly 9,000 cases that blame its talc products — including the company’s iconic Johnson’s Baby Powder &m...
Source: Asbestos and Mesothelioma News - July 13, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Russian Company Brands Asbestos with Trump ’ s Face
The world’s largest producer of chrysotile asbestos is now marketing its signature product with President Donald Trump’s image, according to a recent Facebook post from the Russian mining company Uralasbest. On June 25, the company, which operates a giant asbestos mine in the Ural Mountains in Western Russia, posted photos of its asbestos on palettes wrapped in plastic and stamped with a seal of Trump’s face in red ink. A message of support for Trump and former Environmental Protection Agency (EPA) administrator Scott Pruitt accompanied the photos. In an English translation provided by the Environmental...
Source: Asbestos and Mesothelioma News - July 11, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Surgery Plus HIPEC Only ‘ Potential for Cure ’ of Peritoneal Mesothelioma
This study contributes to a better understanding of how CRS and HIPEC work and who is likely to receive the best benefit from this combination treatment. For patients with the most aggressive peritoneal mesothelioma cancers, additional options — such as immunotherapy or ongoing, post-surgical delivery of chemotherapy into the peritoneal cavity — may be additional treatments to consider. The post Surgery Plus HIPEC Only ‘Potential for Cure’ of Peritoneal Mesothelioma appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - July 10, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Study Details Significant Increase in Asbestos-Related Deaths
Deaths attributed to asbestos exposure — within the United States and worldwide — have been significantly underestimated, according to the latest study by the International Commission of Occupational Health (ICOH). Asbestos is killing more people than anyone thought. Based on the most extensive study to date, occupational asbestos-related diseases killed 39,275 people within the U.S. and 222,321 people throughout the world in 2016. Both figures were more than double the commonly used estimates that stem from various governmental and nongovernmental health agencies. “The asbestos burden is worse than peopl...
Source: Asbestos and Mesothelioma News - July 9, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Cancer Treatment Less Effective in Older Patients
As age increases, so does the risk for cancer. More than half of all cancer cases occur in people over 65. This is especially true for mesothelioma. The average age at diagnosis for pleural mesothelioma — the most common form of the disease — is 69. Despite cancer being more common among the elderly, many cancer treatments work best in younger patients. Researchers now have an idea of why certain cancer treatments don’t work as well in older patients. These important findings were published in June in the medical journal Cell Reports. “While it is clear that primary T cell responses decline in the ...
Source: Asbestos and Mesothelioma News - July 6, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Gene Mutations Dictate Treatment in NCI Clinical Trial
More than 40 patients with mesothelioma have been screened for NCI-MATCH, the novel clinical trial pairing tumor-related gene abnormalities with a drug targeting the corresponding mutation, regardless of cancer type. The multicenter program is the largest precision medicine clinical trial ever conducted, with more than 5,500 patients already participating nationwide. The National Cancer Institute (NCI) sponsors the phase II trial called Molecular Analysis for Therapy Choice (MATCH), which opened in 2015. The study was designed for patients with various solid tumors, myeloma and lymphoma that have progressed after standard-...
Source: Asbestos and Mesothelioma News - July 5, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Research Reveals Immunotherapy More Effective in Men
For mesothelioma patients, immunotherapy is mostly available through clinical trials at this time. Immunotherapy is a relatively new way to treat cancer, and doctors still are learning who will respond best to these novel therapies. Newly released medical research has found men seem to respond better to immunotherapy than women. But this doesn’t mean immunotherapy is off the table for women with mesothelioma. You should learn all you can about how immunotherapy works, why it may or may not be right for you and how you can best prepare yourself if you decide an immunotherapy clinical trial is right for you. Thorough ...
Source: Asbestos and Mesothelioma News - July 3, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Study: Intrapleural Air Flow Can Enhance Mesothelioma CT Scans
Researchers in Australia believe they have discovered a simple way to enhance the accuracy of CT scanning for pleural abnormalities, potentially leading to better diagnostics for mesothelioma cancer. A research team from the University of Western Australia in Perth has shown the sensitivity of CT scans — used in the diagnostic process — can be improved by creating intrapleural air flow. The discovery stems from their six test cases of malignancies, including four patients with pleural mesothelioma. Chest Journal, the official publication of the American College of Chest Physicians, published the study in June. ...
Source: Asbestos and Mesothelioma News - June 29, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

NIH Opening First Mesothelioma Clinical Trial for Lynparza
The National Institutes of Health (NIH) in Bethesda, Maryland, is opening the first mesothelioma clinical trial involving the immunotherapy drug Lynparza (olaparib), a protein inhibitor and targeted therapy already used effectively with breast and ovarian cancers. The phase II clinical trial, for patients previously treated with standard chemotherapy, is designed to gauge the response rate in pleural and peritoneal mesothelioma. Mesothelioma specialist Dr. Raffit Hassan of the National Cancer Institute (NCI) is the senior investigator for the single-center trial, which hopes to enroll at least 40 patients. Earlier research...
Source: Asbestos and Mesothelioma News - June 27, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Personalized Lung Cancer Screening Tool Adds Asbestos Exposure
A University of Michigan and Veterans Affairs research team has developed a novel, personalized lung cancer screening tool that accounts for past asbestos exposure. Asbestos exposure is best known as the primary cause of mesothelioma, but it also significantly increases the chance of developing lung cancer. Adding asbestos to the lung-cancer screening tool also should help identify mesothelioma in its earliest stages, when it is most treatable. Mesothelioma is not usually diagnosed until it has progressed into stage 3 or stage 4, when treatment is more palliative than potentially curative. The tool is designed to better i...
Source: Asbestos and Mesothelioma News - June 26, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Addressing Suicide Among Cancer Patients
The recent suicides of highly regarded fashion designer Kate Spade and television celebrity chef and author Anthony Bourdain remind us this mental health crisis can touch anyone. Cancer patients are no exception. According to the Centers for Disease Control and Prevention (CDC), suicide rates between 1999 and 2016 have risen more than 30 percent in half of the country and by nearly 60 percent in some states. This trend is particularly worrisome for cancer patients because this group has a higher suicide risk than the general public. For mesothelioma patients and the people who care for them, one part of this picture deser...
Source: Asbestos and Mesothelioma News - June 22, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Tremelimumab and Imfinzi Combo Effective for Mesothelioma
The novel immunotherapy drug mixture of tremelimumab and Imfinzi (durvalumab) produced encouraging results in the first phase II mesothelioma clinical trial examining this combination. The study, which included 40 mesothelioma patients in Italy, was published in the June 2018 edition of The Lancet Respiratory Medicine. Similar — or even more promising — results with this combination are expected to follow soon in the United States. “Results from this study are very promising,” investigator Dr. Luana Calabro, Siena University Hospital, told Asbestos.com. “This regimen also has shown a good safe...
Source: Asbestos and Mesothelioma News - June 20, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

‘Supercharged’ Immunotherapy Could Target Mesothelioma Cell Protein
Standard mesothelioma treatment options include surgery, radiation therapy, chemotherapy and multimodal therapy. These standard therapies do not offer a cure for people with mesothelioma, and that’s why scientists continue searching for better ways to treat the disease. Researchers at the Scripps Research Institute in Jupiter, Florida, have created a precision medicine approach that targets a protein on the surface of cancer cells to kill tumors. Although the drug was not specifically designed for mesothelioma patients, it may offer a more effective way to manage the disease in the future. The treatment is a type of...
Source: Asbestos and Mesothelioma News - June 18, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Results of Novel Mesothelioma Drug Presented at ASCO Meeting
A multicenter phase II clinical trial involving the latest orally administered protein inhibitor drug has shown considerable promise in helping control malignant mesothelioma. The effectiveness of tazemetostat was presented last week at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The trial study, which will conclude late 2018, involves 74 previously treated patients with recurring mesothelioma. “We’ve seen benefit for some patients with this treatment and patients who have benefited over a long period of time,” medical oncologist Dr. Marianna Koczywas, City of Hope Cancer T...
Source: Asbestos and Mesothelioma News - June 14, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Nintedanib ‘ Superior ’ to Bevacizumab for Mesothelioma Treatment
Researchers in Austria, Germany and Hungary have added to the growing belief that the anti-cancer drug nintedanib may soon become a significant part of standard-of-care treatment for malignant pleural mesothelioma. In their study published recently in Clinical Cancer Research, nintedanib demonstrated an ability to inhibit the growth and the migration of mesothelioma tumor cells effectively in animal models. “This is a step in the right direction, another part of the evolutionary process of treatment advancements with this difficult disease,” Dr. Balazs Hegedus, department of thoracic surgery, University of Dui...
Source: Asbestos and Mesothelioma News - June 11, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

‘Right to Try Act’ Could Aid Mesothelioma Patients
Patients with mesothelioma may soon find an easier path to experimental drugs and treatments after President Donald Trump signed the “Right to Try Act” into law last week. The new legislation will give terminally ill patients a more direct and quicker line to drugs still awaiting approval from the U.S. Food and Drug Administration (FDA), bypassing the often-cumbersome application process. The law also will protect doctors and pharmaceutical companies from the legal risks of allowing unapproved treatments. The bill was passed by the Senate in August 2017 and cleared the House of Representatives late last month....
Source: Asbestos and Mesothelioma News - June 6, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

EPA Releases New Rules for TSCA Asbestos Review
As part of the latest updates to the reformed Toxic Substances Control Act (TSCA), the U.S. Environmental Protection Agency (EPA) last week proposed new rules for the risk evaluation of asbestos. The EPA released a significant new use rule (SNUR) proposal which would allow the agency to prevent new uses of asbestos, the naturally occurring mineral linked to deadly cancers such as mesothelioma. It is the first time the EPA has issued such an action. The SNUR would require the agency’s approval before asbestos-containing goods can be manufactured, imported or processed. It would grant the EPA power to evaluate the inte...
Source: Asbestos and Mesothelioma News - June 5, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Could Mesothelioma Chemotherapy Ever Be Obsolete?
Oncologist Dr. Arek Dudek at Regions Hospital Cancer Care Center in St. Paul, Minnesota, believes his clinical trial involving a novel immunotherapy combination could change the way doctors treat pleural mesothelioma. Dudek is opening the only Phase II trial evaluating the combination of nivalumab (Opdivo) and ramucirumab (Cyramza) for previously treated mesothelioma patients. “This strategy – if successful, like we think it will be – could make treatment with chemotherapy obsolete,” Dudek told Asbestos.com. “People can be really excited about this one.” He based his optimism on the pote...
Source: Asbestos and Mesothelioma News - June 1, 2018 Category: Environmental Health Authors: Walter Pacheco Source Type: news

Survey: Most Oncologists Discuss Medical Marijuana with Cancer Patients
Medical marijuana continues to be a hot topic among mesothelioma patients and a popular way to cope with disease symptoms and treatment side effects. As more states legalize marijuana for medicinal purposes, more cancer patients are asking their doctors about the natural therapy. A recent survey published in the Journal of Clinical Oncology shows as many as 80 percent of oncologists talk about medical marijuana with their patients. Of the 237 oncologists who responded to the survey, more than half (55 percent) practice in one of the 28 states where medical marijuana is legal. Questions on the survey covered recommendations...
Source: Asbestos and Mesothelioma News - June 1, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Facility Expertise Matters for Mesothelioma Surgery
Patients having aggressive surgery for pleural mesothelioma at high-volume facilities experience fewer complications, shorter hospital stays and lower 30-day readmission rates than those treated at low-volume centers. Overall survival rates were higher and 90-day mortality rates were lower at the high-volume facilities, according to a study published in the June issue of Lung Cancer. The new study, based on data from the National Cancer Database (NCDB), is the largest to compare facility volume with post-surgery outcome for pleural mesothelioma. “In general, going to a high-volume center for oncology care makes sens...
Source: Asbestos and Mesothelioma News - May 30, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

South Carolina J & J Baby Powder-Mesothelioma Case Ends in Mistrial
A South Carolina judge declared a mistrial Friday in a high-stakes case blaming asbestos-contaminated Johnson & Johnson Baby Powder for a woman’s mesothelioma. Jurors failed to reach a unanimous decision in the case of Bertila Boyd-Bostic, who was diagnosed with pericardial mesothelioma at the age of 30 and died 15 months later. Bostic’s husband, Antoine Bostic, sued Johnson & Johnson, talc supplier Imerys Talc America and drug store chain Rite Aid, alleging his wife’s death was caused by years of asbestos exposure from inhaling J&J baby powder. The 12-member jury could only reach a unanimous ...
Source: Asbestos and Mesothelioma News - May 29, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

J & J Loses Second Asbestos in Talcum Powder Lawsuit
Johnson & Johnson suffered its second trial loss in two months Wednesday linking the company’s baby powder to deadly asbestos-related cancer. A Los Angeles jury awarded $21.7 million in compensatory damages to Joanne Anderson, who said she developed mesothelioma after being exposed to asbestos in J&J baby powder laced with the carcinogen. J&J was ordered to pay an additional $4 million in punitive damages Thursday, bringing the total award for Anderson to $25.7 million. The verdict comes less than two months after Johnson & Johnson’s first loss in an asbestos-related talcum powder lawsuit. In ...
Source: Asbestos and Mesothelioma News - May 24, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Novel Mesothelioma Treatment Uses Electrical Fields
Oncologists in 2019 may begin offering patients with pleural mesothelioma a novel, tumor-fighting tool involving electric currents that enhance standard-of-care treatment and extend survival, according to the device manufacturer. Tumor Treating Fields (TTF) is the name of the new technology. It is designed to disrupt cancer cell division through electric fields tuned to specific frequencies. In an ongoing multicenter phase II clinical trial in Europe, TTF has shown an ability in first-line treatment to improve the effectiveness of standard chemotherapy for mesothelioma patients. The trial success has led the manufacturer t...
Source: Asbestos and Mesothelioma News - May 24, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Experts Discuss Unique Side Effects of Immunotherapy
If you have mesothelioma and you’ve already received standard-of-care therapies, you may be considering an immunotherapy clinical trial. If you’re considering this option, a free immunotherapy teleconference is a great place to learn more. CancerCare recently hosted two one-hour education workshops featuring panels of immunotherapy experts. Part I of the teleconference presented an overview of immunotherapy. Part II of the teleconference, which is available online for free, focused exclusively on immunotherapy side effects. Understanding these issues and the role each patient plays in managing their own side ef...
Source: Asbestos and Mesothelioma News - May 21, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

ONCOS-102 Mesothelioma Trial Moves Forward
Oncologists in Spain are recruiting patients for the randomized phase of the pleural mesothelioma clinical trial involving ONCOS-102, the promising immunotherapy vaccine. Optimism surrounding the trial stems from encouraging results obtained recently in the six-patient safety cohort used as a precautionary lead-in. The trial involves the vaccine in combination with standard-of-care chemotherapy for patients with inoperable disease. ONCOS-102 is a scientifically engineered adenovirus that is designed to activate a patient’s immune system to selectively target cancer cells. It is being developed by Targovax, a Scandina...
Source: Asbestos and Mesothelioma News - May 17, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Study Evaluates Systemic Chemotherapy on Peritoneal Mesothelioma
Systemic chemotherapy, either before or after cytoreductive surgery, provided no improvement in long-term survival for patients with peritoneal mesothelioma, according to a recent study. The addition of systemic chemotherapy improved survival at the one-year mark, but there were no benefits at the two-, three- or five-year checkpoints. Systemic chemotherapy uses anti-cancer drugs that are injected into a vein or given by mouth. The median survival of surgical patients who received systemic chemotherapy did not improve, either. “We know surgery is the best option, and if the surgery is successful, chemotherapy may not...
Source: Asbestos and Mesothelioma News - May 15, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Study Reveals Emotional Needs of People Exposed to Asbestos
There is very little information available on the psychological care needs of people with malignant mesothelioma. Even less is known about people who have been exposed to asbestos but do not have mesothelioma. A newly published systematic research review sheds light on the distress people experience in these situations. In March 2018, the American Journal of Industrial Medicine published an article highlighting the need for additional studies. Researchers described what is known about asbestos-affected people and how and why they experience so much mental and emotional distress. Most Affected People Exposed Through Work Th...
Source: Asbestos and Mesothelioma News - May 14, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Peritoneal Mesothelioma Specialist Takes Expertise to South Florida
Dr. Shanel Bhagwandin saw the steady flow of patients who traveled from Southeast Florida to New York’s renowned Mount Sinai Hospital for the specialized treatment of peritoneal mesothelioma cancer. He knew there was a better way, and he just made it happen. Bhagwandin made the 1,200-mile move himself — from Mount Sinai to the Jupiter Medical Center — to start the latest surgical oncology program that specializes in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). “This procedure can make a tremendous difference,” Bhagwandin told Asbestos.com. “And it makes a ...
Source: Asbestos and Mesothelioma News - May 10, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Study: Open-Label Placebos Relieve Fatigue in Cancer Patients
It is common for cancer patients to experience fatigue during and after cancer treatment. Fatigue usually lessens as patients recover, but some patients experience long-term fatigue that gets in the way of the things they want to do. Mesothelioma survivors are among the many cancer patients who cope with fatigue once treatment ends. New research conducted by scientists at the University of Alabama at Birmingham and Harvard Medical School shows cancer-related fatigue can be relieved by a placebo pill. This relief even occurs when patients are aware they are taking a placebo, known as open-label placebo. A placebo is anythin...
Source: Asbestos and Mesothelioma News - May 7, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Samuel Epstein Leaves Legacy of Cancer Prevention
Dr. Samuel Epstein spent his life advocating cancer prevention and fighting against industries that put workers and consumers at risk. For more than 50 years, Epstein raised awareness of preventable causes of cancer. Among his targets was asbestos, a naturally occurring mineral linked to mesothelioma, lung cancer and other deadly conditions. He’s credited for saying the asbestos industry “successfully suppressed and manipulated information on the carcinogenicity and other hazards of asbestos.” In his 1998 book “The Politics of Cancer Revisited,” Epstein discussed the elaborate cover-up that Jo...
Source: Asbestos and Mesothelioma News - May 2, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Researchers Test Aerosol Chemotherapy for Mesothelioma
Chemotherapy can be given in a variety of ways. Now European researchers have added another method to the list for patients with peritoneal mesothelioma: Aerosol chemotherapy sprayed into the belly. A recent study reported outcomes for 24 patients who underwent the novel procedure. Pressurized intraperitoneal aerosol chemotherapy, or PIPAC, shrunk tumors and relieved symptoms in more than half of patients. The study was published in the April edition of BMC Cancer. The researchers believe aerosol chemotherapy can target abdominal cancer better than liquid chemotherapy. PIPAC is not yet available in the U.S., where docto...
Source: Asbestos and Mesothelioma News - April 30, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Multimodal Treatment for Mesothelioma Shows Survival Benefit
This study confirmed, by comparison, the effectiveness of multimodal treatment,” Hassan said. “But you can’t rely [on] what you see in papers. Before choosing, patients have to talk with the oncologist, the surgeon, the pulmonologist, about benefits and risks of treatment.” Benefits of Nintedanib Discussed A second research group at ELCC presented on the benefits of the drug nintedanib in combination with chemotherapy for patients with mesothelioma. The report was part of a phase III clinical trial. Nintedanib, which is marketed as Ofev or Vargatef, is a small-molecule enzyme inhibitor which has sho...
Source: Asbestos and Mesothelioma News - April 27, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

New Tool Determines If Vermiculite Insulation Contains Asbestos
Scientists with the United States Geology Survey (USGS) have created a hand-held spectrometer to determine if vermiculite insulation contains deadly amphibole asbestos. The recent innovation should provide a time-saving technique for commercial and home inspectors. Currently, inspectors must send samples to off-site laboratories before making that determination. “The emphasis was coming up with a method that was both reliable and easier to use,” Gregg Swayze, USGS scientist and lead researcher, told Asbestos.com. “We achieved that goal.” The findings were published in the April 2 edition of America...
Source: Asbestos and Mesothelioma News - April 24, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Yale Alumni Push Back Against Asbestos Tycoon Stephan Schmidheiny
Yale University alumni are pushing again to revoke the honorary degree given to Swiss billionaire Stephan Ernst Schmidheiny, whose asbestos-filled factories in Italy were responsible for the deaths of more than 2,000 people. Schmidheiny, 70, was sentenced to 16 years in prison and fined $15 billion in 2012 by an Italian court that found him negligent in protecting employees and nearby residents from deadly asbestos-related diseases such as mesothelioma. Schmidheiny received his honorary degree from Yale in 1996. In 2014, the university dismissed efforts by the Italy-based Asbestos Victims and Relatives Association and seve...
Source: Asbestos and Mesothelioma News - April 19, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Latest Mesothelioma Immunotherapy Combination Looks Promising
Scientists at the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital have uncovered a novel, two-agent immunotherapy combination that worked surprisingly well in animal models with malignant mesothelioma. The discovery has sparked new optimism for immunotherapy, which has struggled to provide consistently positive results with aggressive cancers such as mesothelioma. “This is the beginning of a new story of hope, a new combination of immunotherapy,” Dr. Mark Poznansky, director of the VIC and associate professor at Harvard Medical School, told Asbestos.com. “It worked quite well in a...
Source: Asbestos and Mesothelioma News - April 17, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Pleurectomy and Decortication the ‘ Way to Go ’ for Mesothelioma
Dr. Pietro Bertoglio and his colleagues at the University Hospital of Pisa stopped performing the aggressive extrapleural pneumonectomy (EPP) surgery for mesothelioma more than a decade ago. They believe it’s long overdue for everyone else to do the same and instead use the less-debilitating pleurectomy/decortication (P/D) procedure. The Journal of Thoracic and Cardiovascular Surgery recently published the University Hospital of Pisa’s 10-year experience using P/D and hyperthermic intrathoracic chemotherapy (HITHOC). Two editorial commentaries from thoracic surgeons in the U.S. accompanied the study from Italy,...
Source: Asbestos and Mesothelioma News - April 16, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Talcum Powder Lawsuit: J & J, Imerys to Pay $80M in Punitive Damages
Johnson & Johnson and talc supplier Imerys SA must pay an additional $80 million in punitive damages to a man who said he developed mesothelioma after using asbestos-contaminated talcum powder, a New Jersey state court jury ruled Wednesday. The court has awarded $117 million in total damages in the case. Last week, a New Brunswick, New Jersey, jury ordered J&J and Imerys to pay $37 million in compensatory damages to plaintiff Stephen Lanzo III and his wife. It was the first trial loss for J&J over allegations that its talc-based products contain deadly asbestos. Last year, a Los Angeles Superior Court ruled in...
Source: Asbestos and Mesothelioma News - April 11, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Mesothelioma Research Results Offer Potential Route to Earlier Detection
Cancer experts have known for decades that asbestos causes mesothelioma. Yet, only 2 to 10 percent of people with prolonged asbestos exposure are diagnosed with pleural mesothelioma, the most common type of the disease. Researchers want to know how the disease actually happens, and what this may tell us about why some people exposed to asbestos develop the disease while others do not. The latest results from the Shukla Research Lab at the pathology and laboratory medicine department at the University of Vermont have shed light on the precise steps for how asbestos fibers lead to mesothelioma. The newly described pathway fr...
Source: Asbestos and Mesothelioma News - April 11, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

5 Key Takeaways from Mesothelioma Expert Teleconference
If you have been diagnosed with mesothelioma, you’re likely seeking information and resources to learn more about the disease. A free one-hour mesothelioma teleconference is a great place to start. CancerCare recently hosted the “Advancements in the Treatment of Mesothelioma” workshop. The session featured five mesothelioma experts, including Dr. Hedy Kindler, director of the mesothelioma program at the University of Chicago Comprehensive Cancer Center. The Mesothelioma Applied Research Foundation co-sponsored the teleconference, which is available online for free. All mesothelioma patients can benefit f...
Source: Asbestos and Mesothelioma News - April 9, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

J & J Loses Talcum Powder Lawsuit
Johnson & Johnson suffered its first loss in an asbestos-related talcum powder lawsuit Thursday after a New Jersey jury ordered the company and its talc supplier to pay $37 million in damages. The jury awarded $30 million in compensatory damages to Stephen Lanzo III, who claims he developed mesothelioma after using Johnson & Johnson’s Shower to Shower and Baby Powder products from 1972 to 2003. His wife, Kendra, was awarded $7 million in damages. Johnson & Johnson was held 70 percent liable in the case, meaning they must pay $25.9 million. France-based talc supplier Imerys SA is liable for the remaining 3...
Source: Asbestos and Mesothelioma News - April 6, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

J & J Loses Case Linking Mesothelioma to Asbestos in Talc
Johnson & Johnson suffered its first loss in an asbestos-related talcum powder lawsuit Thursday after a New Jersey jury ordered the company and its talc supplier to pay $37 million in damages. The jury awarded $30 million in compensatory damages to Stephen Lanzo III, who claims he developed mesothelioma after using Johnson & Johnson’s Shower to Shower and Baby Powder products from 1972 to 2003. His wife, Kendra, was awarded $7 million in damages. Johnson & Johnson was held 70 percent liable in the case, meaning they must pay $25.9 million. France-based talc supplier Imerys SA is liable for the remaining 3...
Source: Asbestos and Mesothelioma News - April 6, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Mesothelioma Clinical Trial Opens with Optimism in South Florida
Dr. Chukwuemeka Ikpeazu at the Sylvester Comprehensive Cancer Center has brought hope — where once there was none — to patients in South Florida with unresectable pleural mesothelioma. Ikpeazu is the principal investigator in the multicenter phase II clinical trial involving the much-anticipated immunotherapy drug durvalumab. Pharmaceutical giant AstraZeneca manufactures the drug under the brand name Imfinzi. “I am optimistic, very, very optimistic that this drug will be effective for these patients,” Ikpeazu told Asbestos.com. “All the data, all the earlier studies, are encouraging.” He...
Source: Asbestos and Mesothelioma News - April 4, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Banning Asbestos Only One Step on a Long Road
Banning all forms of asbestos won’t end the problem of asbestos-related diseases. It is merely a good starting point. As more countries around the world move closer to an outright ban, Australia has become a reminder to guard against false hope. The Australian experience proves how unrelenting this problem is and how much more work must be done. Fifteen years after its much-celebrated ban of the toxic mineral, Australia has just reached its peak of asbestos-related diseases such as malignant mesothelioma cancer. “It took many years, and efforts from many organizations, for a complete ban to be put in place,&rdq...
Source: Asbestos and Mesothelioma News - April 2, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Mesothelioma Clinical Trial Evaluating Selecta ’ s SEL-403 Begins
A clinical trial testing a new therapeutic modality on patients with pleural and peritoneal mesothelioma is officially underway. Selecta Biosciences, a clinical-stage biopharmaceutical company, and the National Cancer Institute (NCI) teamed up for the phase 1 clinical trial under the Cooperative Research and Development Agreement. The trial will evaluate safety and tolerability of SEL-403, Selecta’s investigational new drug combination consisting of a potent anti-tumor agent (LMB-100) and a drug that prevents an immune response (SVP-Rapamycin). LMB-100 and SVP-Rapamycin have been studied separately in clinical trials...
Source: Asbestos and Mesothelioma News - March 29, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Immunotherapy Drugs Causing Vision Issues
The U.S. Food and Drug Administration (FDA) is investigating the potential for three immunotherapy drugs to cause retinal detachment and vision loss. The FDA will consider adding eye toxicities to the warning labels for pembrolizumab (Keytruda), nivolumab (Opdivo) and ipilimumab (Yervoy), which have shown promise in clinical trials involving malignant mesothelioma. All three have already been approved by the FDA for use with metastatic melanoma. Keytruda and Opdivo also have approval for head and neck cancers, colorectal cancers and certain non-small cell lung cancers. The FDA used its Adverse Event Reporting System (FAERS...
Source: Asbestos and Mesothelioma News - March 27, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

New Targeted Therapy May Benefit Mesothelioma Patients
For newly diagnosed mesothelioma patients, standard treatment options include surgery, radiation therapy, chemotherapy and multimodal therapy, which combines these options in various ways. However, more physicians are adding precision medicine to the mix, including targeted therapies such as immunotherapy or drugs aimed at a specific genetic mutation in a tumor. Clinical trials have shown a new drug called AZD5363 attacks a gene that is mutated in some mesothelioma tumors. The drug was not designed for mesothelioma patients, but it may offer another mesothelioma treatment avenue in the future. Limited Options Inspire New T...
Source: Asbestos and Mesothelioma News - March 23, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Parasite Drug Shows Effectiveness Against Mesothelioma
Dr. Antonio Giordano believes his team has cleared the path to the next breakthrough in the treatment of malignant pleural mesothelioma. The advancement involves a new use for an old drug, pyrvinium pamoate, which doctors have successfully used for more than 50 years to treat infections of pinworm parasite. “This drug that no one expected to be involved with mesothelioma is potentially a new weapon against this aggressive type of tumor,” Giordano told Asbestos.com. “Our findings are exciting, very exciting. This one can move forward.” Giordano is the founder and director of the Sbarro Health Researc...
Source: Asbestos and Mesothelioma News - March 21, 2018 Category: Environmental Health Authors: Daniel King Source Type: news